Literature DB >> 8961989

Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. Medical Research Council Rectal Cancer Working Party.

.   

Abstract

BACKGROUND: Survival rates after surgery for rectal cancer remain at about 40% at 5 years from diagnosis. The aim of this study was to find out whether local recurrence rate could be reduced and survival increased by a moderately high dose of preoperative radiotherapy in patients with locally advanced, but otherwise operable, carcinoma of the rectum.
METHODS: We carried out a prospective randomised trial of surgery alone (n = 140) versus surgery preceded by 40 Gy radiotherapy (n = 139) given in 20 fractions of 2 Gy over 4 weeks. The patients, from 20 regional centres throughout the UK, were enrolled between 1981 and 1989, and followed up for a minimum of 5 years or to death.
FINDINGS: 217 patients died, 114 of 140 allocated surgery alone and 103 of 139 allocated preoperative radiotherapy: median survival times were 24 months and 31 months, respectively. The hazard ratio for overall survival was 0.79 (95% CI 0.60-1.04, p = 0.10). At 5 years' follow-up 65 patients allocated surgery alone and 50 who received preoperative radiotherapy had local recurrence (hazard ratio 0.68 [0.47-0.98], p = 0.04); the corresponding numbers of patients with distant recurrence were 67 and 49 (hazard ratio 0.66 [0.46-0.95], p = 0.02). There was a significant benefit of radiotherapy on disease-free survival (hazard ratio 0.76 [0.58-1.0], p = 0.05). There was no increase in postoperative or late complications in the radiotherapy group.
INTERPRETATION: Our results provide further evidence that preoperative radiotherapy can reduce the rate of local recurrence of rectal cancer in patients with locally advanced disease. However, survival results are still equivocal, and so we must await the results of a meta-analysis of all radiotherapy trials from which precise and definitive results, particularly for survival, may be obtained.

Entities:  

Mesh:

Year:  1996        PMID: 8961989

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  53 in total

Review 1.  Calculating the number needed to treat for trials where the outcome is time to an event.

Authors:  D G Altman; P K Andersen
Journal:  BMJ       Date:  1999-12-04

Review 2.  Optimising treatment for resectable rectal cancer: is preoperative therapy beneficial?

Authors:  S Y Ngan
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Complications of perineal surgery.

Authors:  James W Ogilvie; Rocco Ricciardi
Journal:  Clin Colon Rectal Surg       Date:  2009-02

4.  Resectability of rectal cancers still fixed after radio-chemotherapy: evaluation by digital rectal examination, MRI, and intraoperative examination.

Authors:  G Baatrup; P Pfeiffer; Birgitte Svolgaard; H A Jensen
Journal:  Int J Colorectal Dis       Date:  2005-06-21       Impact factor: 2.571

Review 5.  Evolving management of colorectal cancer.

Authors:  Jochem van der Voort van Zijp; Harald J Hoekstra; Marc D Basson
Journal:  World J Gastroenterol       Date:  2008-07-07       Impact factor: 5.742

6.  [Reduction of local recurrence and distant metastases in advanced rectal carcinoma by preoperative radiotherapy--results of a randomized study by the MRC (Medical Research Council)].

Authors:  R Fietkau
Journal:  Strahlenther Onkol       Date:  1997-09       Impact factor: 3.621

7.  Neoadjuvant radiation and chemotherapy in rectal cancer does not increase postoperative complications.

Authors:  G Valero; J A Luján; Q Hernández; M De Las Heras; E Pellicer; A Serrano; P Parrilla
Journal:  Int J Colorectal Dis       Date:  2003-07-15       Impact factor: 2.571

Review 8.  Advances and challenges in treatment of locally advanced rectal cancer.

Authors:  J Joshua Smith; Julio Garcia-Aguilar
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

9.  Preoperative radiotherapy improves survival for patients undergoing total mesorectal excision for stage T3 low rectal cancers.

Authors:  Conor P Delaney; Ian C Lavery; Antonio Brenner; Jeffrey Hammel; Anthony J Senagore; Robert B Noone; Victor W Fazio
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

10.  Adjuvant therapy for rectal cancer.

Authors:  Smitha S Krishnamurthi; Yuji Seo; Timothy J Kinsella
Journal:  Clin Colon Rectal Surg       Date:  2007-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.